Bavarian Nordic gets FDA approval for chikungunya vaccine
Bavarian Nordic (OTCPK:BVNRY) has received FDA approval for its vaccine Vimkunya for the prevention of chikungunya. The virus-like particle, or VLP, vaccine is approved for people aged 12 and older.
Medical Design and Outsourcing21h
Nasal vaccine devices: Design and regulatory need-to-knows
Nasal vaccine devices have the potential to offer more convenient and more effective protection against a variety of viruses.
Frontiers21h
Molecular and Phylogenetic Insights for Diagnostics and Vaccine Development
Viral diseases remain a significant global health challenge, causing widespread morbidity and mortality. Advances in ...